During the past decade, National Center for Tuberculosis and Lung Diseases conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 2 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Center for Tuberculosis and Lung Diseases" #1 sponsor was "Fundació Institut Germans Trias i Pujol" with 4 trials, followed by "Global Alliance for TB Drug Development" with 3 trials sponsored, "Foundation for Innovative New Diagnostics, Switzerland" with 2 trials sponsored, "Emory University" with 1 trials sponsored and "IUATLD, Inc" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Center for Tuberculosis and Lung Diseases" #1 collaborator was "National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia" with 4 trials as a collaborator, "Epicentre" with 2 trials as a collaborator, "Harvard Medical School (HMS and HSDM)" with 2 trials as a collaborator, "Institute of Tropical Medicine, Belgium" with 2 trials as a collaborator and "Interactive Research and Development" with 2 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "National Center for Tuberculosis and Lung Diseases" are "Tuberculosis" (6 trials), "Tuberculosis, Multidrug-Resistant" (6 trials), "Tuberculosis, Pulmonary" (4 trials), "Tuberculosis, MDR" (3 trials) and "Close Contacts of Active Tuberculosis" (1 trials). Many other conditions were trialed in "National Center for Tuberculosis and Lung Diseases" in a lesser frequency.

Most popular intervention types in "National Center for Tuberculosis and Lung Diseases" are "Drug" (8 trials), "Biological" (1 trials), "Diagnostic Test" (1 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bedaquiline" (4 trials), "Moxifloxacin" (4 trials), "Pyrazinamide" (4 trials), "Placebo" (3 trials) and "Clofazimine" (2 trials). Other intervention names were less common.

The vast majority of trials in "National Center for Tuberculosis and Lung Diseases" are 14 trials for "All" genders.

Currently, there are NaN active trials in "National Center for Tuberculosis and Lung Diseases". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in National Center for Tuberculosis and Lung Diseases, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in National Center for Tuberculosis and Lung Diseases, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".